DK3119782T3 - 2,7-diazaspiro[3.5]nonanforbindelser - Google Patents

2,7-diazaspiro[3.5]nonanforbindelser Download PDF

Info

Publication number
DK3119782T3
DK3119782T3 DK15710486.0T DK15710486T DK3119782T3 DK 3119782 T3 DK3119782 T3 DK 3119782T3 DK 15710486 T DK15710486 T DK 15710486T DK 3119782 T3 DK3119782 T3 DK 3119782T3
Authority
DK
Denmark
Prior art keywords
diazaspiro
alkyl
sulfonyl
nonan
group
Prior art date
Application number
DK15710486.0T
Other languages
English (en)
Inventor
Taeye Bart De
Katrien Princen
Witte Koen De
Emilie Blanche
Hasane Ratni
Mark Rogers-Evans
Gerard Griffioen
Original Assignee
Remynd Nv Bio Incubator
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remynd Nv Bio Incubator filed Critical Remynd Nv Bio Incubator
Application granted granted Critical
Publication of DK3119782T3 publication Critical patent/DK3119782T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (15)

1. Forbindelse med formlen (I) eller en stereoisomer, en enantiomer, et racemat, eller en tautomer deraf,
hvor, n er et heltal valgt blandt 0, 1, 2 og 3; R1 er valgt fra gruppen bestående af Ci^alkyl, halogen, halogenCi_6alkyl og halogenCi_6alkyloxy; R3 er valgt fra gruppen bestående af Ce^aryl, hydrogen, Ci-6alkyl, C3-i2cycloalkyl, heterocyclyl, heteroaryl, C6-i2arylCi-6alkyl, C6-i2arylCi-6alkylC6-i2aryl, halogen, hydroxyl, -OR18, -SR19, halogenCi_6alkyl, halogenCi^alkyloxy, amino, -NR20R21 og cyano; hvor C6-i2aryl-, Ci_6alkyl-, C3_i2cycloalkyl-, heterocyclyl-, heteroaryl-, Ce-i2arylCi-6alkyl- eller C6-i2arylCi-6alkylC6-i2arylgruppen kan være ikke-substitueret eller substitueret med en eller flere Z1; L1 er valgt fra gruppen bestående af -SO2-, -CO-,
hvor * angiver hvor L1 er bundet til L2; og ** angiver hvor L1 er bundet til azetidinringen; og hvor A1 er S eller O; q er et heltal valgt blandt 0, 1, 2 og 3; L6 er -CO- eller -S02-, hver R er uafhængigt valgt fra gruppen bestående af halogenCi^alkyloxy, -OR , halogen, hydrogen, Ci_6alkyl, halogenCi_6alkyl, C3_i2cycloalkyl, C6-i2aryl, Cé-narylCi- 6alkyl, heterocyclyl, heteroaryl, hydroxyl, SR19, cyano, amino, -NR20R21, -CO2R22, -C(O)NR20R21, -C(0)R22, -S(0)R22, -S(0)2R22, -SO2NR20R21, nitro, -NR23C(0)R22, -R24-C(O)NR20R21, -NR23S(0)2R22, og -NR23C(O)NR20R21; hvor to R2 sammen med det atom, der er bundet i, kan danne en mættet eller umættet 5-, 6- eller 7-leddet ring; og hvor mindst et carbonatom eller heteroatom i denne ring, C6-i2aryl, C3-8cycloalkyl, heterocyclyl, heteroaryl kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 eller S(0)2; R4 er valgt fra gruppen bestående af C6-i2aryl, hydrogen, Ci_6alkyl, C3_i2cycloalkyl, heterocyclyl, heteroaryl, C6-i2arylCi-6alkyl, C6-i2arylCi-6alkylC6-i2aryl, halogen, hydroxyl, -OR18, -SR19, halogenCi-6alkyl, halogenCi-6alkyloxy, amino, -NR20R21 og cyano; og hvor C6-i2aryl-, Ci_6alkyl-, C3_i2cycloalkyl-, heterocyclyl-, heteroaryl-, Ce-i2arylCi_6alkyl- eller C6-i2arylCi-6alkyl(V,-i2aryl gruppen kan være ikke-substitueret eller substitueret med en eller flere Z2; L2 er en enkeltbinding eller en gruppe med formlen (i);
hvor venstre side af gruppen med formlen (i) er bundet til R3, og højre side deraf er bundet til azetidinringens nitrogenatom; og hvor, m er et heltal valgt blandt 0, 1, 2 og 3; w er et heltal valgt blandt 0, 1, 2 og 3; L er en enkeltbinding eller er valgt fra gruppen bestående af -O- og -NR -; R8 er valgt fra gruppen bestående af hydrogen, Ci^alkyl, halogen, hydroxyl, -OR18, -SR19, halogenCi-6alkyl og halogenCi-6alkyloxy; R er valgt fra gruppen bestående af hydrogen, Ci-6alkyl, halogen, hydroxyl, -OR , -SR19, halogenCi-6alkyl og halogenCi_6alkyloxy; eller R8 og R9 danner sammen med det carbonatom, de er bundet til, en mættet eller umættet 3-, 4-, 5-, 6- eller 7-leddet ring; R10 er valgt fra gruppen bestående af hydrogen, Ci-6alkyl, halogen, hydroxyl, -OR18, -SR19, halogenCi_6alkyl og halogenCi_6alkyloxy; R11 er valgt fra gruppen bestående af hydrogen, Ci^alkyl, halogen, hydroxyl, -OR18, -SR19, halogenCi-6alkyl og halogenCi-6alkyloxy; eller R10 og R11 danner sammen med det carbonatom, de er bundet til, en mættet eller umættet 3-, 4-, 5-, 6- eller 7-leddet ring; R12 er valgt fra gruppen bestående af hydrogen og Ci-6alkyl; L3 er valgt fra gruppen bestående af -SO2-, -PO4- og -PO3-; L4 er en enkeltbinding eller er valgt fra gruppen bestående af -(CR15R16)t-, -O- og -NR17-; hvor t er et heltal valgt blandt 1,2 og 3; R15 er valgt fra gruppen bestående af hydrogen, Ci_6alkyl, halogen, hydroxyl, -OR18, -SR19, halogenCi_6alkyl og halogenCi_6alkyloxy; R16 er valgt fra gruppen bestående af hydrogen, Ci_6alkyl, halogen, hydroxyl, -OR18, -SR19, halogenCi_6alkyl og halogenCi_6alkyloxy; eller R15 og R16 danner sammen med det carbonatom, de er bundet til, en mættet eller umættet 3-, 4-, 5-, 6- eller 7-leddet ring; R17 er valgt fra gruppen bestående af hydrogen og Ci-6alkyl; hvor mindst en af L3, L4 ikke er en enkeltbinding; og hvor R4 ikke er methyl, når L4 er en enkeltbinding; hver R18 er uafhængigt valgt fra gruppen bestående af Ci-ealkyl, C2-6alkenyl, C2-6alkynyl, C6-i2aryl, C3_8cycloalkyl, C6-i2arylCi_6alkyl, heterocyclyl, heteroaryl, heterocyclylCi_6alkyl, heteroarylCi-6alkyl og cyanoCi-ealkyl; hvor mindst et carbonatom eller heteroatom i Ci^alkyl-, C2-6alkenyl-, C2-6alkynyl-, C6-i2aryl-, C3_8cycloalkyl-, C6-i2arylCi-6alkyl-, heterocyclyl-, heteroaryl-, heterocyclylCi_6alkyl-, hctcroarylCi-ealkyl- eller cyanoCi_6alkylgruppen kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 or S(0)2; hver R19 er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-i2aryl, C3.8cycloalkyl, C6-i2arylCi_6alkyl, heterocyclyl, heteroaryl, heterocyclylCi_6alkyl, heteroarylCi-6alkyl og cyanoCi_6alkyl; hvor mindst et carbonatom eller heteroatom i Ci_6alkyl-, C2-6alkenyl-, C2-6alkynyl-, C6-i2aryl-, C3-8cycloalkyl-, C6-i2arylCi-6alkyl-, heterocyclyl-, heteroaryl-, heterocyclylCi-6alkyl-, heteroarylCi_6alkyl- eller cyanoCi_6alkylgruppen kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 or S(0)2; hver R20 er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-i2aryl, C3-8cycloalkyl, C6-i2arylCi-6alkyl, heterocyclyl, heteroaryl, heterocyclylCi_6alkyl og heteroarylCi-6alkyl; hvor mindst et carbonatom eller heteroatom i Ci-6alkyl-, C2-6alkenyl-, C2-6alkynyl-, C6_i2aryl-, C3-8cycloalkyl-, C6-i2arylCi_6alkyl-, heterocyclyl-, heteroaryl-, heterocyclylCi-6alkyl- eller heteroarylCi-6alkylgruppen kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 or S(0)2; hver R21 er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C6-i2aryl, C3-8cycloalkyl, C6-i2arylCi-6alkyl, heterocyclyl, heteroaryl, heterocyclylCi_6alkyl og heteroarylCi-6alkyl; hvor mindst et carbonatom eller heteroatom i Ci_6alkyl-, C2-6alkenyl-, C2-6alkynyl-, C6-i2aryl-, C3-8cycloalkyl-, C6-i2arylCi-6alkyl-, heterocyclyl-, heteroaryl-, heterocyclylCi-6alkyl- eller heteroarylCi-6alkylgruppen kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 or S(0)2; eller hvor R20 og R21 sammen med det nitrogenatom, de er bundet til, danner en 5-, 6-eller 7-leddet heterocyclyl; og hvor mindst et carbonatom eller heteroatom i heterocyclylgruppen kan være oxideret for at danne mindst en C=0, C=S, N=0, N=S, S=0 or S(0)2; hver R22 er uafhængigt valgt fra gruppen bestående af hydrogen, hydroxyl, Ci_ealkyl, C2-6alkenyl, C2-6alkynyl, C6-i2aryl, C3-8cycloalkyl, Ce-narylCi-ealkyl, heterocyclyl, heteroaryl, heterocyclylCi-ealkyl og hcteroarylC. 1 -ealkyl; hvor mindst et carbonatom eller heteroatom i Ci_6alkyl-, C2-6alkenyl-, C.2-6alkynyl-, C6-i2aryl-, C3_8cycloalkyl-, C6-i2arylCi_6alkyl-, heterocyclyl-, heteroaryl-, heterocyclylCi_6alkyl- eller heteroarylCi_6alkylgruppen kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 or S(0)2; hver R23 er uafhængigt valgt fra gruppen bestående af hydrogen, Ci-ealkyl, C2-6alkenyl, C2-ealkynyl, C6-i2aryl, C3-8cycloalkyl, C6-i2arylCi-6alkyl, heterocyclyl, heteroaryl, heterocyclylCi^alkyl og heteroarylCi_6alkyl; og hvor mindst et carbonatom eller heteroatom i Ci_6alkyl-, C2-6alkenyl-, C2-6alkynyl-, C6-i2aryl-, C3-8cycloalkyl-, C6-i2arylCi_6alkyl-, heterocyclyl-, heteroaryl-, heterocyclylCi-ealkyl- og heteroarylCi-6alkylgruppen kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 or S(0)2; hver R24 er uafhængigt valgt fra gruppen bestående af Ci_6alkylen, C2-6alkenylen, C2-éalkynylen, C6-i2arylen, C3.8cycloalkylen, C6-i2arylenCi-6alkylen*, heterocyclylen, heteroarylen, heterocyclylenCi-6alkylen* og heteroarylenCi-6alkylen*; hvor * angiver, hvor R24 er bundet til CO; hvor mindst et carbonatom eller heteroatom i Ci_6alkylen-, C2-6alkenylen-, C2-6alkynylen-, C6-i2arylen-, C3.8cycloalkylen-, C6-i2arylenCi-6alkylen- , heterocyclylen-, heteroarylen-, heterocyclylenCi^alkylen- eller heteroarylenCi. 6alkylengruppen kan være oxideret for at danne mindst én C=0, C=S, N=0, N=S, S=0 eller S(0)2; hver Z1 er uafhængigt valgt fra gruppen bestående af halogenCi_6alkyloxy, -OR18, halogen, hydrogen, Ci_6alkyl, halogenCi-6alkyl, C3-i2cycloalkyl, C6-i2aryl, C6-i2arylCi-6alkyl, heterocyclyl, heterocyclylCi_6alkyl, heteroaryl, heteroarylCi_6alkyl, hydroxyl, -SR19, cyano, amino, -NR20R21, -C02R22, -C(O)NR20R21, -C(0)R22, -S(0)R22, -S(0)2R22, -SO2NR20R21, nitro, -NR23C(0)R22, -R24-C(O)NR20R21, -NR23S(0)2R22 og -NR23C(O)NR20R21; hvor to Z1 sammen med det atom, de er bundet til, kan danne en mættet eller umættet 5-, 6- eller 7-leddet ring; og hvor mindst et carbonatom eller heteroatom i Ci_6alkyl-, C3_i2cycloalkyl-, C6-i2aryl-, C6-i2arylCi_6alkyl-, heterocyclyl-, heterocyclylCi_6alkyl-, heteroaryl- eller heteroarylCi_6alkylgruppen kan være oxideret for at danne mindst en C=0, C=S, N=0, N=S, S=0 or S(0)2; hver Z2 er uafhængigt valgt fra gruppen bestående af halogenCi-6alkyloxy, -OR18, halogen, hydrogen, Ci_6alkyl, halogenCi_6alkyl, C3_i2cycloalkyl, C6-i2aryl, C6-i2arylCi_ 6alkyl, heterocyclyl, heterocyclylCi_6alkyl, heteroaryl, heteroarylCi_6alkyl, hydroxyl, -SR19, cyano, amino, -NR20R21, -C02R22, -C(O)NR20R21, -C(0)R22, -S(0)R22, -S(0)2R22, -SO2NR20R21, nitro, -NR23C(0)R22, -R24-C(O)NR20R21, -NR23S(0)2R22 og -NR23C(O)NR20R21; hvor to Z2 sammen med det atom, de er bundet til, kan danne en mættet eller umættet 5-, 6- eller 7-leddet ring; og hvor mindst et carbonatom eller heteroatom i Ci^alkyl-, C3.i2cycloalkyl-, C6_i2aryl-, Ce-12arylCi-ealkyl-, heterocyclyl-, heterocyclylCi_6alkyl-, heteroaryl- eller heteroarylCi_6alkylgruppen kan være oxideret for at danne mindst en C=0, C=S, N=0, N=S, S=() or S(0)2; med det forbehold, at forbindelsen ikke er N-(l-methylethyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-fluorphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-phenyl-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(4-methoxyphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, (lH-benzotriazol-5-yl)-{7-[2-(3-chlor-phenyl)-ethansulfonyl]-2,7-diaza-spiro[3.5]non-2-yl}-methanon, N-(4-methoxyphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-cyanophenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, 7-(methylsulfonyl)-N-phenyl-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-fluorphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid eller et solvat, hydrat, farmaceutisk acceptabelt salt eller en prodrug deraf.
2. Forbindelse ifølge krav 1, der har strukturformlen (IA)
hvor L1, L2, L4, n, R1, R3 og R4 har samme betydning som defineret i krav 1.
3. Forbindelse ifølge et hvilket som helst af kravene 1 eller 2, hvor L1 er -SO2-.
4. Forbindelse ifølge et hvilket som helst af kravene 1 til 3, der har strukturformlen (IB) 1
hvor, L2, L4, n, R1, R3 og R4 har samme betydning som defineret i et hvilket som helst af kravene 1 til 3.
5. Forbindelse ifølge et hvilket som helst af kravene 1 til 4, der har strukturformlen (ID)
hvor, n, R1, R3 og R4 har samme betydning som defineret i et hvilket som helst af kravene 1 til 4.
6. Forbindelse ifølge krav 1, der har strukturformlen (IC)
hvor L1, L3, F4, m, n, R1, R3, R4, R8 og R9 har samme betydning som defineret i krav 1.
7. Forbindelse ifølge krav 1, der har strukturformlen (IE)
hvor n, L1, L3, L4, R1, R3, R4 og L6 har samme betydning som defineret i krav 1.
8. Forbindelse ifølge krav 1, der har strukturformlen (IF)
hvor n, F1, F4, R1, R3, R4 og F6 har samme betydning som defineret i krav 1.
9. Forbindelse ifølge et hvilket som helst af kravene 1, 6, 6 til 8, hvor F6 er en enkeltbinding.
10. Forbindelse ifølge krav 1, hvor F1 er
11. Forbindelse ifølge et hvilket som helst af kravene 1 til 10, hvor forbindelsen er valgt fra gruppen bestående af 2,7-Bis((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 2-((4-Fluorphenyl)sulfonyl)-7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 2-((4-(Difluormethoxy)phenyl)sulfonyl)-7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 7-((4-Methoxyphenyl)sulfonyl)-2-((4-propoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 2-((4-Chlorphenyl)sulfonyl)-7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 2-(4-Fluorphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)ethanon; (4-Chlorphenyl)(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)methanon; (3,4- Difluorphenyl)(7-((4-methoxyphenyl)sulfbnyl)-2,7-diazaspiro[3.5 ] nonan-2-yl)methanon; (4-Fluorphenyl)(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)methanon; l-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-phenylethanon; 1-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-phenylbutan-l-on; 4,4,4-Trifluor- 1- (7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)butan-l-on; 1-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspbo[3.5]nonan-2-yl)-2-methyl-2-phenylpropan-l-on; (7-((4-Methoxyphenyl) sulfonyl)-2,7 -diazaspiro [3.5] nonan-2- yl) (1 - phenylcyclopropyl)methanon; 3-(4-Fluorphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)propan-l-on; 2-(3-Methoxyphenyl)-1-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylpropan-l-on; 1-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-metbyl-2-(pyridin-3-ylmethoxy)propan-l-on; 2-Hydroxy-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-(pyridin-2-yl)propan-l-on; 2-(4-Methoxyphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)propan-l-on; 1-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspbo[3.5]nonan-2-yl)-2-methyl-2-(o-tolyl)propan-l-on; Chroman-4-yl(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)methanon; (S)- 2- (4-Fluorphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-methylbutan-l-on; 2-(2-Methoxyphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)propan-l-on; 2-(2-Methoxyphenyl)-1-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylpropan-l-on; (7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)(l,2,3,4-tetrahydronaphthalen-l-yl)methanon; 2-(4-Chlorphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)propan-l-on; 2-(4-Chlorphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylpropan-l-on; (7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)(l-phenylcyclopentyl)methanon; 2-(3,5-Difluorphenyl)-1 -(7 - ((4-methoxyphenyl) sulfonyl)-2,7 -diazaspiro[3.5]nonan-2-yl)propan-l-on; 2-(3-Chlorphenyl)-l-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-2-methylpropan-l-on; 5-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(2,2,2-trifluorethyl)-l,2,4-thiadiazol; 3-(4-Chlorbenzyl)-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(3,4-Difluorbenzyl)-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-thiadiazol; 3-Cyclopropyl-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)- 1.2.4- thiadiazol; 3-Butyl-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)- 1.2.4- thiadiazol; 5-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(3- (trifhiormethyl)benzyl)-1,2,4-thiadiazol; 3-(4-Methoxyphenyl)-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 5-(7-((4-Methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(pyrazin-2-yl)-l,2,4-thiadiazol; 3-(4-Chlorphenyl)-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-thiadiazol; 3-(l-(4-Fluorphenyl)cyclopropyl)-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((4-(methylthio)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 7-((4-(Difluormethoxy)phenyl)sulfonyl)-2-((4-ethoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 2-((4-Chlorphenyl)sulfonyl)-7-((4-(difluormethoxy)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 7-((4-(Difhiormethoxy)phenyl)sulfonyl)-2-((4-fluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 7-((4-(Difluormethoxy)phenyl)sulfonyl)-2-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 7-((4-Ethoxyphenyl)sulfonyl)-2-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 7-((4-Chlorphenyl)sulfonyl)-2-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 2,7-Bis((4-(difluormethoxy)phenyl) sulfonyl) -2,7 -diazaspiro [3. 5 ] nonan; 2- ((4- (Difluormethoxy)phenyl)sulfonyl)-7-((4-ethoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 7-((4-Chlorphenyl)sulfonyl)-2-((4-(difluormethoxy)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 2-((4-(Difluormethoxy)phenyl)sulfonyl)-7-((4-fluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan; 6-Chlor-2-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)benzo [d] thiazol; 6-Chlor-2- (7- ((4-ethoxyphenyl) sulfonyl)-2,7-diazaspiro [3.5] nonan-2-yl)benzo [d] thiazol; 6-Chlor-2- (7 -((4- (difluormethoxy)phenyl) sulfonyl)-2,7 -diazaspiro[3.5]nonan-2-yl)benzo[d]thiazol; 6-Chlor-2-(7-((4-(methylthio)phenyl)sulfonyl)- 2.7- diazaspiro[3.5]nonan-2-yl)benzo[d]thiazol; 3-(l-(4-Fluorphenyl)ethyl)-5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)- 5-(7-((4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; N-(4-((2-(3-(4-fluorbenzyl)-l,2,4-thiadiazol-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)sulfonyl)phenyl)acetamide; 3-(4-Fluorbenzyl)-5-(7-((4-(methylsulfonyl)phenyl)sulfonyl)- 2.7- diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 5-(7-((2,4-Difluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 5-(7-((3,4-Dimethoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((2-methoxy-5-methylphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-thiadiazol; 5-(7-((5-Chlor-2-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((3-(trifluormethyl)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4- Fluorbenzyl)-5-(7-((4-(trifluormethyl)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-(m-tolylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((2-fhiorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)- 1.2.4- thiadiazol; 5-(7-((4-Ethylphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-(o-tolylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-thiadiazol; 5-(7-((4-(Tert-butyl)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((3-fluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 5-(7-((2,5-Dimethoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fhiorbenzyl)-l,2,4-thiadiazol; 5-(7-((2,5-Difluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 5-(7-((2,6-Difluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 5-(7-((3,4-Difluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((3-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 5-(7-((5-Fluor-2-methylphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 2-Ethoxy-5-((2-(3-(4-fluorbenzyl)-l,2,4-thiadiazol-5-yl)-2,7-diazaspiro[3.5]nonan-7- yl) sulfonyl)benzonitrile; 3 - (4-Fluorbenzyl) - 5 - (7 - ((4-methoxy- 3 -(trifluormethyl)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((2-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-thiadiazol; 5-(7-((3-Chlor-4-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((3-(methylsulfonyl)phenyl)sulfonyl)- 2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 5-(7-((3,5-Difluorphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; Methyl-3-((2-(3-(4-fluorbenzyl)-l,2,4-thiadiazol-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)sulfonyl)benzoate; 5-(7-((4-(Difluormethoxy)phenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)- 1.2.4- thiadiazol; 5-(7-((5-Fluor-2-methoxyphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 5-(7-((4-Ethoxy-3-methylphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((4-methoxy-3-methylphenyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-(pyridin-3-ylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)- 1.2.4- thiadiazol; 4-((2-(3-(4-Fluorbenzyl)-l,2,4-thiadiazol-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)sulfonyl)-3,5-dimethylisoxazol; 3-(4-Fluorbenzyl)-5-(7-(thiophen-2-ylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1,2,4-thiadiazol; 5-(7-((5-Chlorthiophen-2-yl)sulfonyl)-2,7- diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-(thiophen-3-ylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((5-methylthiophen-2-yl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 3-(4-Fluorbenzyl)-5-(7-((3,3,3-trifluorpropyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-l,2,4-thiadiazol; 5-(7-((Cyclohexylmethyl)sulfonyl)-2,7-diazaspiro[3.5]nonan-2-yl)-3-(4-fluorbenzyl)-l,2,4-thiadiazol; 4-((2-(3-(4-Fluorbenzyl)-l,2,4-thiadiazol-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)sulfonyl)morpholin; og et solvat, hydrat eller famaceutisk acceptabelt salt deraf.
12. Farmaceutisk sammensætning, der omfatter et eller flere farmaceutiske hjælpestoffer og en terapeutisk virkningsfuld mængde af en forbindelse ifølge et hvilket som helst af kravene 1 til 11 eller en terapeutisk virkningsfuld mængde af en forbindelse valgt fra gruppen bestående af N-(l-methylethyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-(3-fluorphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-phenyl-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-(4-methoxyphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(4-methoxyphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-cyanophenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, 7-(methylsulfonyl)-N-phenyl-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-fluorphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, og et solvat, hydrat eller famaceutisk acceptabelt salt deraf.
13. Forbindelse ifølge et hvilket som helst af kravene 1 til 11 eller forbindelse valgt fra gruppen bestående af N-(l-methylethyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3,5]nonan-2-carboxamid; N-(3-fluorphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-phenyl-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-(4-methoxyphenyl)- 7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(4-methoxyphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-cyanophenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, 7-(methylsulfonyl)-N-phenyl-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-fluorphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, og et solvat, hydrat eller famaceutisk acceptabelt salt deraf, eller farmaceutisk sammensætning ifølge krav 12 til anvendelse som et lægemiddel.
14. Forbindelse ifølge et hvilket som helst af kravene 1 til 11 eller forbindelse valgt fra gruppen bestående af N-(l-methylethyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3,5]nonan-2-carboxamid; N-(3-fluorphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-phenyl-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-(4-methoxyphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, (lH-benzotriazol-5-yl)-{7-[2-(3-chlor-phenyl)-ethanesulfonyl]-2,7-diaza-spiro[3.5]non-2-yl}-methanon, N-(4-methoxyphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-cyanophenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, 7-(methylsulfonyl)-N-phenyl-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-fluorphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, og et solvat, hydrat eller famaceutisk acceptabelt salt deraf; eller farmaceutisk sammensætning ifølge krav 12 til anvendelse som medicin til forebyggelse og/eller behandling af stofskifteforstyrrelser og/eller neurodegenerative lidelser og/eller proteinfejlfoldningsforstyrrelser.
15. Forbindelse ifølge et hvilket som helst af kravene 1 til 11 eller forbindelse valgt fra gruppen bestående af N-(l-methylethyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3,5]nonan-2-carboxamid; N-(3-fluorphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-phenyl-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid; N-(4-methoxyphenyl)-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, (lH-benzotriazol-5-yl)-{7-[2-(3-chlor-phenyl)-ethanesulfonyl]-2,7-diaza-spiro[3.5]non-2-yl}-methanon, N-(4-methoxyphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-cyanophenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, 7-(methylsulfonyl)-N-phenyl-2,7-diazaspiro[3.5]nonan-2-carboxamid, N-(3-fluorphenyl)-7-(methylsulfonyl)-2,7-diazaspiro[3.5]nonan-2-carboxamid, og et solvat, hydrat eller famaceutisk acceptabelt salt deraf; eller farmaceutisk sammensætning ifølge krav 12 til anvendelse som medicin til forebyggelse og/eller behandling af diabetes mellitus, Parkinsons sygdom, Alzheimers sygdom, diffus Lewy Bodys sygdom, amyotrofisk lateralsklerose, Niemann-Picks sygdom, Hallervorden-Spatz' syndrom, Downs syndrom, neuroaxonal dystrofi, multipel systematrofi, Huntingtons sygdom, frontotemporallapdegeneration (FTLD), multipel systematrofi, cystisk fibrose, Creutzfeld-Jacobs sygdom, nedsat glucosetolerance, hyperglykæmi, hypoglykæmi, glyceraldehyd-3-phosphat-dehydrogenase-deficiens, hyperinsulinisme, nedsat insulinproduktion, nedsat insulinfølsomhed, stofskiftesyndrom, insulinresistenssyndrom, fedme, lipidoser, hjertelipidoser, dyslipidæmi, fedtlever, lipodystrofi, kardiovaskulære sygdomme og hypertension.
DK15710486.0T 2014-03-17 2015-03-17 2,7-diazaspiro[3.5]nonanforbindelser DK3119782T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14160344 2014-03-17
PCT/EP2015/055494 WO2015140132A1 (en) 2014-03-17 2015-03-17 2,7-diazaspiro[3.5]nonane compounds

Publications (1)

Publication Number Publication Date
DK3119782T3 true DK3119782T3 (da) 2018-03-12

Family

ID=50287962

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15710486.0T DK3119782T3 (da) 2014-03-17 2015-03-17 2,7-diazaspiro[3.5]nonanforbindelser

Country Status (17)

Country Link
US (2) US9617264B2 (da)
EP (1) EP3119782B1 (da)
JP (2) JP6574438B2 (da)
CN (1) CN106103439B (da)
AU (1) AU2015233642B2 (da)
CA (1) CA2941196C (da)
DK (1) DK3119782T3 (da)
EA (1) EA032470B1 (da)
ES (1) ES2666173T3 (da)
HR (1) HRP20180585T1 (da)
HU (1) HUE038764T2 (da)
NO (1) NO3119782T3 (da)
PL (1) PL3119782T3 (da)
PT (1) PT3119782T (da)
RS (1) RS57129B1 (da)
SI (1) SI3119782T1 (da)
WO (1) WO2015140132A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201416352D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
US11149022B2 (en) 2017-10-17 2021-10-19 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2019126559A1 (en) 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP7714665B2 (ja) * 2021-01-29 2025-07-29 コリア リサーチ インスティチュート オブ ケミカル テクノロジー ベンゾチアゾール及びベンズイミダゾール誘導体、薬学的に許容可能な塩、その製造方法及びそれを有効成分として含む医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
US20080070888A1 (en) 2006-09-15 2008-03-20 Mckittrick Brian A Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
PH12012501800A1 (en) * 2010-03-19 2012-12-10 Pfizer 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
CN104379563B (zh) * 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
DK2861566T3 (da) 2012-06-13 2017-02-27 Hoffmann La Roche Nye diazaspirocycloalkaner og azaspirocycloalkaner

Also Published As

Publication number Publication date
JP2017507986A (ja) 2017-03-23
US9750745B2 (en) 2017-09-05
CN106103439A (zh) 2016-11-09
HUE038764T2 (hu) 2018-11-28
RS57129B1 (sr) 2018-07-31
EA201691539A1 (ru) 2017-01-30
WO2015140132A1 (en) 2015-09-24
NO3119782T3 (da) 2018-06-30
ES2666173T3 (es) 2018-05-03
AU2015233642B2 (en) 2017-08-03
EP3119782A1 (en) 2017-01-25
PT3119782T (pt) 2018-04-17
JP2019147834A (ja) 2019-09-05
EA032470B1 (ru) 2019-05-31
JP6574438B2 (ja) 2019-09-11
US20170015665A1 (en) 2017-01-19
PL3119782T3 (pl) 2018-07-31
CA2941196A1 (en) 2015-09-24
CN106103439B (zh) 2019-03-08
AU2015233642A1 (en) 2016-09-08
CA2941196C (en) 2019-09-03
US20170157137A1 (en) 2017-06-08
HRP20180585T1 (hr) 2018-07-13
SI3119782T1 (en) 2018-06-29
US9617264B2 (en) 2017-04-11
EP3119782B1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US20200140400A1 (en) Oxadiazole compounds
DK3119782T3 (da) 2,7-diazaspiro[3.5]nonanforbindelser
HUP0203766A2 (hu) 5-Piridil-1,3-azol vegyületek, ezek előállítási eljárása és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
KR20140105445A (ko) 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
KR20140072879A (ko) 신규한 약한 rock 억제제
WO2017157882A1 (en) Serine biosynthetic pathway inhibitors
CN120641397A (zh) 稠合吡咯基磺酰胺化合物
WO2024033479A1 (en) (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders
WO2016083490A1 (en) Compounds for the treatment of amyloid-associated diseases
HK1227398B (en) 2,7-diazaspiro[3.5]nonane compounds
HK1227398A1 (en) 2,7-diazaspiro[3.5]nonane compounds
US20240002351A1 (en) Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
WO2024062043A1 (en) Substituted phenothiazines as ferroptosis inhibitors
CN121001993A (zh) 核转运调节剂
WO2026013191A1 (en) Novel ferroptosis inhibitors
WO2026013198A1 (en) Oxazole derivatives for oral administration